Understanding Liver Cancer

Liver cancer develops in the cells of the liver, which is responsible for storing nutrients, filtering blood, and producing proteins that help with digestion. The most common type, hepatocellular carcinoma (HCC), accounts for 85% of primary liver cancers. Other types include cholangiocarcinoma (affecting bile ducts) and fibrolamellar carcinoma (a rare subtype in younger patients without cirrhosis).

In India, liver cancer is predominantly driven by chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), which together account for about 80% of cases. Cirrhosis—whether from viral hepatitis, alcohol-related liver disease, or aflatoxin exposure—is present in 80–90% of patients at diagnosis. Early detection through regular screening in high-risk populations and modern multimodal treatments have improved survival outcomes significantly.

The prognosis and treatment options depend on the cancer stage, liver function, and patient performance status. Curative approaches (resection, ablation, transplant) are possible in early stages, while advanced disease may benefit from systemic therapy or combination approaches. Adjuvant therapy after resection has been shown to reduce recurrence and improve long-term survival.

Types of Liver Cancer

Signs & Symptoms

1. Abdominal pain or swelling: Discomfort in the upper right abdomen, often due to tumor growth or liver enlargement
2. Jaundice: Yellowing of skin and eyes caused by elevated bilirubin from impaired liver function
3. Unexplained weight loss: Rapid, unintentional loss of body weight over weeks to months
4. Loss of appetite: Persistent lack of hunger or early satiety during meals
5. Persistent fatigue: Unusual tiredness not relieved by rest, linked to liver dysfunction
6. Dark urine or pale stools: Color changes indicating bilirubin buildup or bile flow obstruction
7. Nausea and vomiting: Often worse in advanced disease or with liver decompensation
8. Swelling in legs and feet: Fluid accumulation (ascites, edema) from liver failure or portal hypertension
9. Itching (pruritus): Often severe and associated with jaundice

Many patients with early liver cancer show no symptoms. Regular screening via ultrasound and AFP levels is critical for at-risk individuals (HBsAg+ or HCV+ patients, cirrhosis).

Risk Factors for Liver Cancer

Liver cancer risk is highest in patients with chronic liver disease, particularly cirrhosis. The following factors significantly increase risk:

Risk stratification based on AASLD, EASL, and APJGH guidelines; India-specific epidemiology from GLOBOCAN 2020, ICMR, and published cohorts.

How Liver Cancer Is Diagnosed

Diagnosis combines imaging, blood tests, and sometimes biopsy. For at-risk patients, surveillance programs can detect early tumors when curative treatment is still possible.

Staging & Prognosis (BCLC + AJCC)

Liver cancer staging uses the Barcelona Clinic Liver Cancer (BCLC) system, which integrates tumor burden, liver function, and patient performance status to guide treatment and predict survival. The AJCC TNM system is also widely used.

BCLC staging incorporates tumor size, number, vascular invasion, extrahepatic spread, liver function (Child-Pugh), and performance status. Treatment allocation and prognosis are determined by BCLC stage. AJCC TNM (8th edition) uses tumor, node, metastasis criteria for staging; BCLC is preferred for treatment planning in HCC.

Treatment Options for Liver Cancer

Surgical Resection

Partial hepatectomy removes the tumor and a margin of normal liver tissue. Safe when estimated remnant liver volume is adequate (≥25% in healthy liver, ≥40% in cirrhotic). Achieved via open or minimally invasive (laparoscopic/robotic) approach.

Best outcomes in BCLC-0 and BCLC-A. 5-year survival: 50–70% after curative resection in early stage. Recurrence common (50–70% at 5 years) and managed with repeat resection, ablation, or systemic therapy.

Contraindications: vascular invasion, extrahepatic metastases, decompensated cirrhosis. Pre-operative assessment critical (hepatic reserve, portal pressure gradient).

• Intraoperative ultrasound for margin assessment
• Hepatic artery ligation to reduce bleeding
• No standard adjuvant chemotherapy; consider systemic therapy per risk factors

Liver Transplantation

Orthotopic liver transplant removes entire cirrhotic liver and implants donor liver. Eliminates both cancer and underlying cirrhosis; second-best option for HCC within Milan criteria (single ≤5 cm or up to 3 nodules ≤3 cm) or expanded criteria.

5-year survival: 60–80% with transplant in early HCC. Excellent long-term outcomes. Requires lifelong immunosuppression.

Major constraints in India: organ shortage, cost (₹20–30 lakh+), long waitlist. Living-donor liver transplant (LDLT) available in major centers but limited donor pool. Reserved for BCLC-0/A disease when resection not feasible.

• Calcineurin inhibitors (tacrolimus, cyclosporine) for immunosuppression
• Mycophenolate mofetil (MMF) as adjunctive immunosuppression
• Tacrolimus dosing: 0.05–0.1 mg/kg/day in divided doses; target trough 5–15 ng/mL early post-transplant

Radiofrequency Ablation (RFA) & Microwave Ablation (MWA)

Percutaneous needle-based technique that delivers thermal energy to kill tumor cells. RFA uses high-frequency electrical current; MWA uses microwave energy. Performed under ultrasound or CT guidance.

Best for BCLC-0 and early BCLC-A (nodules ≤3–5 cm). Complete necrosis rates: 90–95% for tumors <3 cm, lower for larger lesions. Can be repeated. Minimal invasiveness; same-day discharge possible.

Advantages: repeatability, lower cost than resection, suitable for high-risk surgical patients. Disadvantages: local recurrence higher than resection, limited to ≤3 lesions, requires expertise.

• Conscious sedation/general anesthesia during procedure
• Prophylactic antibiotics if risk factors present
• No systemic chemotherapy; adjuvant systemic therapy per protocol

Transarterial Chemoembolization (TACE)

Delivered via catheter to hepatic artery. Chemotherapy (doxorubicin ± cisplatin) mixed with embolic material (iodized oil, drug-eluting beads). Starves tumor of blood while delivering high-dose chemotherapy locally.

Standard for BCLC-B (intermediate stage). Can be used bridging to transplant or in select BCLC-C cases. Typically repeated every 4–6 weeks until complete response or progression.

Complete response rates: 30–50% with repeated sessions. 2-year overall survival: 60–80% in BCLC-B. Complications: hepatic decompensation, acute hepatitis, hepatorenal syndrome (rare but serious).

• Doxorubicin 50 mg per session
• Iodized oil (Lipiodol) 3–6 mL per session
• Drug-eluting beads (DEBs) as alternative embolic agent
• Cisplatin 25–50 mg per session in some protocols

Sorafenib

Oral tyrosine kinase inhibitor (TKI) targeting RAF, VEGF, FLT3, KIT. Blocks tumor angiogenesis and cell proliferation. SHARP trial (2008) landmark study showing OS benefit in advanced HCC.

Standard first-line for BCLC-C and some BCLC-B cases. Dose: 400 mg twice daily (fasting state). Median OS with sorafenib: 10.7 months vs. 7.9 months with placebo.

Adverse effects: hand-foot skin reaction (30–40%), diarrhea, fatigue, hypertension. Dose adjustments often needed. Monitor BP, renal function, skin.

• Sorafenib 400 mg PO BID (with 1-hour pre/post food gap)

Lenvatinib

Oral multi-kinase inhibitor (VEGFR, FGF, RET, KIT). Approved as first-line for advanced HCC based on REFLECT trial (2018). Non-inferior to sorafenib with earlier radiological response.

Dose: 12 mg daily for body weight ≥60 kg, 8 mg daily for <60 kg (common in India). Median TTP: 7.4 months; median OS: 13.6 months.

Adverse effects: proteinuria, hypertension, fatigue, nausea. Requires baseline and ongoing urine protein monitoring. May be better tolerated than sorafenib for some patients.

• Lenvatinib 8–12 mg PO once daily (per body weight)

Atezolizumab + Bevacizumab

Combination immunotherapy + anti-angiogenic. Atezolizumab (anti-PD-L1 checkpoint inhibitor) + bevacizumab (anti-VEGF). IMbrave150 trial (2020) showed superior OS vs. sorafenib (14.7 vs. 13.2 months) in treatment-naive BCLC-B/C.

Increasingly used as first-line for advanced disease, especially in immunocompetent patients. Given IV every 2 weeks (atezolizumab 1200 mg + bevacizumab 15 mg/kg).

Adverse effects: immune-related events (fatigue, hepatitis, colitis), hemorrhage, hypertension. Requires monitoring for immune-related AEs. Contraindicated in untreated HBV/HCV (reactivation risk).

• Atezolizumab 1200 mg IV every 2 weeks
• Bevacizumab 15 mg/kg IV every 2 weeks

Transarterial Radioembolization (TARE)

Selective internal radiation therapy (SIRT) using yttrium-90 microspheres delivered via hepatic artery. High local radiation dose; systemic toxicity minimal. Emerging option for BCLC-B/C.

Response rates: 50–80% (by mRECIST). Can be bridging or standalone. Limited availability in India; more common in developed countries.

Adverse effects: transient abdominal pain, nausea. Rare hepatic decompensation if significant underlying dysfunction.

• Yttrium-90 microspheres (glass or resin-based), dose calculated per liver volumes and uptake

Systemic Chemotherapy

Conventional chemotherapy (doxorubicin, 5-FU, cisplatin) has limited role in HCC due to poor response rates and toxicity. Combination regimens (FOLFOX: 5-FU/leucovorin + oxaliplatin) occasionally used in select cases.

Not recommended as first-line. Primarily research interest or compassionate use in advanced disease when TKIs/immunotherapy contraindicated.

Outcomes: response rates 10–20%, median OS 8–10 months. Significant toxicity. Largely superseded by targeted and immunotherapy approaches.

• Doxorubicin 60 mg/m² IV every 3–4 weeks (historical)
• 5-FU 400–500 mg/m² bolus + 2400–3000 mg/m² infusion weekly

Adjuvant Therapy

Post-resection systemic therapy reduces recurrence and improves OS. STORM trial (2020) showed sorafenib as adjuvant in high-risk patients (microvascular invasion, poor differentiation) improves RFS. Atezolizumab + bevacizumab also being studied.

Recommended post-resection if high-risk features (vascular invasion, poor differentiation, large size, advanced cirrhosis). Typically started 4–12 weeks after surgery.

Median RFS improvement: ~4–6 months with adjuvant TKI. OS benefit emerging from longer follow-up studies.

• Sorafenib 400 mg PO BID as adjuvant (per STORM trial)
• Atezolizumab + bevacizumab in clinical trials

Why Adjuvant Therapy Matters

Liver cancer has high recurrence rates even after complete resection. Microvascular invasion (MVI), poor histologic grade, large tumor size, and advanced cirrhosis predict early recurrence. Adjuvant systemic therapy targets microscopic residual disease and circulating tumor cells, reducing progression risk.

The STORM trial (2020) demonstrated that adjuvant sorafenib improved recurrence-free survival (RFS) by ~4 months in high-risk HCC post-resection. Real-world data from Asia shows OS benefit emerging with longer follow-up. Combination approaches (atezolizumab + bevacizumab) are under investigation. In India, adjuvant therapy is increasingly recommended for high-risk patients to optimize long-term outcomes and reduce liver transplant wait time by preventing advanced recurrence.

A Day at HealOnco for Liver Cancer Care

Cost of Liver Cancer Treatment in India

Costs vary by treatment modality, hospital tier, location, and whether complications arise. Figures below are representative; actual costs may differ. Government schemes (Ayushman Bharat, state-specific) may cover portions.

Costs are approximate and reflect typical out-of-pocket expenses in 2026 across government and private hospitals in metros. Advanced therapy costs may be offset by health insurance (Ayushman Bharat covers up to ₹5 lakh per year for eligible patients; state insurance varies). Newer agents (lenvatinib, atezolizumab+bevacizumab) increasingly available via programs in major centers, reducing patient burden. Please confirm exact costs with chosen facility.

Our Liver Cancer Specialists

Our Centres

Modern vs. Traditional Approaches

Pros and Cons of Each Treatment Option

Surgical Resection: Pros: curative intent for early disease, excellent 5-year survival (50–70%) if complete resection achieved. Cons: requires adequate remnant liver, surgical risk in cirrhotic patients, high recurrence rate (50–70%), not suitable for advanced stage or poor liver function.

Radiofrequency Ablation (RFA): Pros: minimally invasive, repeatability, outpatient procedure, suitable for poor surgical candidates, cost-effective. Cons: limited to tumors ≤3–5 cm, lower complete necrosis for large lesions, local recurrence higher than resection (10–15% annually), requires expertise.

Liver Transplantation: Pros: eliminates both cancer and cirrhosis, best outcomes for very early HCC, excellent long-term survival (60–80%). Cons: severe organ shortage in India, prolonged waitlist, high cost (₹20–40 lakh), lifelong immunosuppression required, ethical considerations, LDLT limited by donor availability.

TACE (Transarterial Chemoembolization): Pros: effective for intermediate stage, can be repeated, response in 50–70% of cases, extends median OS to 20+ months in BCLC-B. Cons: not curative, requires repeated procedures (3–4 sessions minimum), hepatic decompensation risk, contraindicated if portal vein thrombosis, less effective in advanced disease.

Sorafenib: Pros: oral administration, proven OS benefit in advanced HCC (median 10.7 months), no hospitalization, can continue if tolerated. Cons: expensive (₹1–2 lakh/month), hand-foot skin reaction in 30–40%, diarrhea and fatigue common, requires BP monitoring, modest benefit in some patients.

Lenvatinib: Pros: earlier radiological response than sorafenib, non-inferior OS (13.6 months), may be better tolerated by some, oral once-daily dosing. Cons: expensive (₹1.5–2.5 lakh/month), proteinuria (requires monitoring), hypertension, similar cost and side-effect burden to sorafenib.

Atezolizumab + Bevacizumab: Pros: superior OS vs. sorafenib (14.7 months), dual mechanism (immunotherapy + anti-angiogenic), emerging first-line option. Cons: very expensive (₹2–4 lakh/month), immune-related toxicities, requires close monitoring, contraindicated in untreated HBV/HCV, IV infusion every 2 weeks.

Adjuvant Therapy: Pros: reduces recurrence risk (4–6 month improvement in RFS), improves long-term OS in high-risk patients, prevents advanced recurrence. Cons: additional treatment burden, toxicity while patient recovering from surgery, requires monitoring, cost, not all patients benefit equally.

TARE (Yttrium-90 Radioembolization): Pros: high local radiation, low systemic toxicity, can treat larger tumors than ablation. Cons: limited availability in India, high cost, requires specialized expertise, long hospitalization, hepatic decompensation possible if poor liver function.

Side Effects and How HealOnco Manages Them

Read the full side effects guide for Liver Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Liver Cancer Treatment in Top Cities

Liver Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. www.nature.com
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. www.journal-of-hepatology.eu
3. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. aasldpubs.onlinelibrary.wiley.com
4. Kudo M, Ueshima K, Chan S, et al. Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A randomized phase 3 trial. J Hepatol. 2022;77(6):1546–1556. www.journal-of-hepatology.eu
5. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. www.nejm.org
6. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. www.gastrojournal.org
7. GLOBOCAN 2020: Global Cancer Observatory. International Agency for Research on Cancer (IARC), World Health Organization. gco.iarc.who.int
8. Greten TF, Sangro B. Targets and clinical pathways in hepatocellular carcinoma. Gastroenterology. 2021;160(6):1908–1920. www.gastrojournal.org
9. Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular carcinoma after resection. Ann Surg. 2015;261(3):547–555. journals.lww.com
10. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. www.nejm.org
11. Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: A systematic review and meta-analysis. Ann Surg Oncol. 2007;14(9):2386–2395. link.springer.com
12. Parikh ND, Marshall VD, Singal AG, et al. Hepatocellular Carcinoma Screening and Diagnosis. J Clin Oncol. 2020;38(11):1152–1163. ascopubs.org